United States 
Canada
EU
UKWe’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Functional and Long-Term Survival Benefit of AMX0035 in ALS
Lead Author: Sabrina Paganoni, MD, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: September 30, 2020
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Lead Author: Sabrina Paganoni, MD, PhD
Published: New England Journal of Medicine
Date: September 3, 2020
Clinical Trial Design for a Phase II, Randomized Placebo-Controlled Trial of AMX0035 in Alzheimer’s Disease
Lead Author: Kent L. Leslie
Published: Alzheimer’s Association International Conference (AAIC)
Date: July 24, 2018
Clinical Trial Design for a Phase II, Randomized, Placebo-Controlled Trial of AMX0035 in Amyotrophic Lateral Sclerosis (CENTAUR)
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: International Symposium on ALS-MND (MNDA)
Date: December 9, 2017
Evaluation of AMX0035, a Novel Combination Therapy for the Treatment of Neurodegenerative Diseases, in Cellular Models of Friedreich’s Ataxia
Lead Author: Kent L. Leslie
Published: International Ataxia Research Conference
Date: September 29, 2017
AMX0035, a Novel Combination Therapeutic Candidate for Treatment of Primary Mitochondrial Diseases
Lead Author: Kent L. Leslie
Published: United Mitochondrial Disease Foundation Mitochondrial Medicine
Date: June 29, 2017